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Abstract: Background: The use of antiretroviral drugs (ARV) to prevent mother-to-child HIV transmission (PMTCT) 
promises to be effective. However, limited data on the adverse effects of ARV among pregnant women and pregnancy 
outcomes have been reported in clinical practice. 
Objectives: This study aimed to assess adverse effects and outcomes among pregnant HIV-infected women receiving 
antiretroviral drugs for either antiretroviral therapy (ART) or PMTCT. 
Study Design: This cohort study was at Chonburi Hospital, Thailand, in 2002-2006. 
Results: A total of 246 pregnant HIV-infected women with the median age (range) of 27 (16-41) years were included in 
this study. ART was initiated in 16.3% for treatment during ANC, 66.7% for PMTCT during ANC, and 17.1% for 
PMTCT in labor. Adverse effects, especially anemia, were significantly associated with continuing combined ART in 
pregnancy (p<0.001). 88.9% delivered normal-term neonates. The prevalence of pre-term delivery was 10.2%. Overall, 24 
adverse events from 21 pregnant women (8.5%) were noted. A significantly higher prevalence of pre-term delivery was 
noted in the groups continuing combined ART, or initiating of PMTCT during labor rather than ANC (p=0.02). The inci-
dence of low Apgar scores was 3.6%, and these were associated with initiation of PMTCT during labor (p=0.004). 
Conclusion: Adverse ARV events were more numerous among the pregnant women who needed ART than PMTCT. 
ANC is beneficial and strongly recommended for all pregnant HIV-infected women for better pregnancy outcomes. 
Keywords: HIV, Adverse effects, antiretroviral drugs, pregnancy, PMTCT. 
INTRODUCTION 
  In Thailand, the prevalence of HIV among pregnant 
women reached a peak of 2.35% in 1995, and was 0.9% in 
2005, with a cumulative 12,213 HIV-infected children via 
mother-to-child transmission (MTCT) up to 2006. Zi-
dovudine (AZT), one of the nucleoside reverse transcriptase 
(NRTI), reduced the risk of HIV mother-to-child transmis-
sion by nearly 70% in 1994 [1], and had been used in most 
Thai hospitals since 1999. The efficacy of adding a single 
dose of nevirapine (NVP) to oral AZT prophylaxis for preg-
nant women in labor, with or without a dose for the infant, to 
reduce vertical HIV transmission, was studied in Thailand, in 
2001-2003.  The observed 80% reduction led to the early 
interruption of the placebo-placebo group enrollment. On the 
basis of these findings [2], and for other logistical reasons, 
the Thai Ministry of Public Health has recommended NVP 
administration for both mother and infant. Increased routine 
use of antiretroviral therapy (ART) has led to a dramatic and 
sustained decrease in mortality and morbidity in HIV infec-  
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tions, and the risk of MTCT.  The national prevention of 
mother-to-child transmission (PMTCT) program estimated 
the rate of perinatal HIV transmission in Thailand was 
0.87% in 2005.  
  It is currently recommended that HIV infected pregnant 
women receive similar HAART regimens to non-pregnant 
women, other than for considerations of potential adverse 
effects on the fetus [3]. Almost 80% of pregnant women 
experienced one or more typical adverse effects of antiretro-
viral drugs (ARV), such as anemia, nausea/vomiting, 
aminotransferase elevation, or hyperglycemia [2]. Concerns 
were raised following liver failure with maternal death re-
ported in a randomized study of NVP use in pregnancy with 
CD4 count > 250 cells/μL, by an AIDS Clinical Trials Group 
(ACTG) [4]. In addition, the data are conflicting, as to 
whether combination ART during pregnancy is associated 
with adverse pregnancy outcomes, such as pre-term delivery 
[5]. Knowledge of the potential adverse effects of ART, spe-
cifically for pregnant women and their fetuses, is very im-
portant when considering antiretroviral regimens, especially 
now a variety of regimens are widely prescribed for pregnant 
HIV-infected women. This study was conducted to review, 
retrospectively and prospectively, the adverse effect of 
antiretroviral therapy among pregnant HIV-infected women 
and their pregnancy outcomes in a clinical setting.  Pregnancy Outcomes Among HIV Cases on Antiretrovirals  The Open AIDS Journal, 2009, Volume 3    9 
METHODOLOGY 
  The cohort study was conducted at  Chonburi Hospital, 
near the famous tourist city of Pattaya, Thailand. The study 
was approved by the Ethics Committees of Chonburi Hospi-
tal and the Faculty of Tropical Medicine, Mahidol Univer-
sity. The study cohort comprised pregnant HIV-infected 
women who attended an antenatal care clinic (ANC), deliv-
ered, or terminated pregnancy at Chonburi Hospital, and 
received ART for either continued treatment or the initiation 
of PMTCT, between 1 January 2001 - 31 December 2006. 
The inclusion criteria were age  15 years, asymptomatic 
HIV infection with accepted baseline conditions (i.e. hemo-
globin level >8.0 g/dL, alanine aminotransferase (ALT) level 
<35 U/L) and no severe concomitant disease (e.g. malig-
nancy), which would complicate an assessment of adverse 
effects during pregnancy. All patients were encouraged to 
attend hospital ANC regularly. Their clinical status was as-
sessed in compliance with the national PMTCT program, 
which included intrapartum, perinatal, and neonatal ART. 
  Data were collected using questionnaires/case record 
forms to gather general demographic information, pregnancy 
and medical history, and self-assessments of any adverse 
events during pregnancy. Antenatal care information, includ-
ing concomitant drugs, adverse effects and laboratory data 
(i.e. CD4+ cells count, hematology, liver function tests, kid-
ney function, urine analysis, etc.) were collected with clini-
cal-oriented decisions in clinical practice. Regularly, com-
plete blood count and liver function tests were monitored 
every 2 and 3 months, respectively during ANC. All tox-
icities associated with ART use were graded according to the 
National Institute of Allergy and Infectious Disease Division 
of AIDS Table for Grading the Severity of Adult and Pediat-
ric Adverse Events, a descriptive scale used in all clinical 
trials developed and/or sponsored by the ACTG to standard-
ize reporting of adverse events. The scale ranges from grade 
1- mild, grade 2- moderate, grade 3- severe, to grade 4- po-
tentially life threatening [6]. The outcomes of pregnancy--
abortion, stillbirth, pre-term delivery, birthweight, Apgar 
score, and birth defects--were assessed. All data were en-
tered and analyzed using the statistical software package Epi 
Info 2002, revision 2. Categorical variables were compared 
using Pearson 
2 test. Quantitative variables were compared 
using the t-test for independent samples or the Mann-
Whitney U test, according to the distribution characteristics 
(symmetrical or skewed, respectively). A p-value <0.05 was 
considered statistically significant. 
RESULTS 
  246 pregnant HIV-infected women were divided into 3 
groups: 1) receiving or continuing treatment with combined 
ARV, 2) ARV initiated for PMTCT, as scheduled or during 
ANC, 3) ARV only in labor due to lack of, or inadequate 
ANC. The maternal characteristics of the 246 pregnant HIV-
infected women are shown in Table 1. Their age range was 
16-41 years (median 27 years). The majority (61.8%) were 
in the age group 20-29 years, followed by 30-39 years 
(29.3%). The rate of teenage pregnancy was 8.1%. The ma-
jority of the pregnant women were currently in spousal rela-
tionships (60.16%), while 7.3% were separated and 1.2% 
widowed. 0.4% reported having multiple sex partners. 
Among the women in spousal relationships, 54% of their 
current spouses were also HIV seropositive whereas 46% 
were not. 29.3% had no income and most of the pregnant 
women had an average monthly income <10,000 Baht. Re-
garding HIV seroconversion, 73.2% were firstly detected 
when attending ANC, 15% prior to the current pregnancy, 
and 11.8% during labour. 
  Among the 37 pregnant women who had known their 
HIV serostatus before the current pregnancy, 19 (51.4%) had 
experience with ARV; 16 continued combined ART, 2 had 
already withdrawn from ART, and one had used AZT plus a 
single dose of NVP once for PMTCT in the previous preg-
nancy. The other 18 (48.6%) pregnant women had no experi-
ence of ARV. Regarding the ART regimens used by 16 
pregnant HIV-infected women, 2NRTIs + NVP (21.6%), 
2NRTIs + efavirenz (EFV) (13.5%) and 2NRTIs + boosted 
indinavir (IDV/r) (8.1%) were noted. EFV was stopped and 
substituted with NVP among 4 pregnant women at 8, 11, 23, 
and 25 weeks' gestation; however, one did not stop taking 
EFV because of late presentation at ANC (35 weeks' gesta-
tion). Among the 180 pregnant women whose HIV-
seroconversion was firstly detected during ANC, the median 
gestational age was 19.5 weeks; 83.9% were detected before 
or at 28 weeks' gestation. 98.2% were in WHO clinical stage 
[7] 1 (asymptomatic), or CDC classification [8] A. Median 
CD4 count was 325.5 cells/L; 13.3% of these were <200 
cells/L. One pregnant woman with a CD4 count of 2 (0%) 
cells/l, was classified as WHO clinical stage 3 (or CDC 
stage B), with perianal abscess and herpes labialis. Five 
(2.0%) pregnant women had late latent syphilis, and 15 
(6.1%) of pregnant women had HBV coinfections. 
  Of the 246 pregnant women in ANC, 40 (16.3%) re-
ceived combined ART, 164 (66.7%) PMTCT regimens, and 
42 only PMTCT in labor, because of irregular or no ANC. 
Of those receiving PMTCT during ANC, only 76 (46.3%) 
started PMTCT before or at 28 weeks; 88 (53.7%) started 
after 32 weeks' gestation. The common combined ART 
regimen used in this study was AZT+ lamivudine (3TC)+ 
NVP (50%) followed by AZT+3TC+IDV/r (20%). Other 
regimens included stavudine (d4T)+3TC +NVP, 
d4T+3TC+IDV/r and didanosine (ddI)+3TC+ NVP. Among 
164 pregnant HIV-infected women receiving PMTCT during 
ANC, 118 (72%) received AZT + single dose NVP; 36 
(22%) received AZT + single dose NVP with tailed end of 
AZT+3TC or AZT+ ddI extending for 2-4 weeks' postpar-
tum, to prevent NNRTI resistance mutation; the remaining 
6% received AZT alone. Of 42 pregnant women who initi-
ated PMTCT in labor, 38 (90.5%) received AZT + single 
dose NVP. Two cases received AZT alone, and another 2 
received single-dose NVP in labor. 
Adverse ARV Events During Pregnancy 
  Overall, 24 adverse ARV related events were docu-
mented from 21 (8.5%, 95%CI: 5.4%-12.8%) pregnant HIV-
infected women. The prevalence of each adverse event is 
shown in Fig. (1); 13 (5.3%) pregnant women developed 
anemia, 4 (1.6%) nausea and vomiting, 3 (1.2%) dyslipide-
mia (1 also reported gestational DM), and 1 (0.4%) hepato-10    The Open AIDS Journal, 2009, Volume 3  Areechokchai et al. 
toxicity and rash. No pregnant HIV-infected women initiat-
ing PMTCT in labor reported an adverse event. The preva-
lence of adverse events among pregnant women receiving 
combined ART (32.5%), and those starting PMTCT during 
ANC (4.9%), was significantly different (P value < 0.001). 
Table 2 compares adverse events among 40 pregnant HIV-
infected women receiving combined ART vs 164 pregnant 
HIV-infected women starting PMTCT during ANC. Table 3 
compares adverse events among 161 pregnant HIV-infected 
women receiving ARV grouped by CD4-cells counts during 
ANC of < 200 vs  200 cells/μL. Anemia was significantly 
more common among pregnant women with CD4 cells 
counts < 200 cells/μL (17.2%) than those with counts  200 
cells/μL (P value =0.04). 
Anemia 
  Twenty-two of 204 (10.8%) developed anemia (cut-off 
haemoglobin level  9.4 g/dl; ACTG grading; 13 (60%) of 
these developed anemia after 4 weeks' ARV exposure. The 
cause of anemia among the other 9 was not identified, and 
occurred before ART. The median red cell mean corpuscle 
volume (MCV) among 13 pregnant women with ARV-
related anemia was slightly increased, from 81.5 to 86.7%, 
whereas among the pregnant women with anemia of uniden-
tified cause, it was lower, and decreased slightly from 71.9 
to 68.8%. Of the women with ARV-related anemia, 10 were 
classified as ACTG severity grade 1, 2 were grade 2, and 1 
was grade 4. The median duration from AZT initiation to 
anemia detection was 5 (range: 4-9) weeks. Regarding man-
agement of anemia, 3 were given blood transfusions; 2 were 
given reduced AZT dosage, and 2 were changed to d4T in-
stead of AZT. 
Other Adverse Events 
  Nausea and vomiting were documented in only 4 (1.6%) 
of 246 pregnant women after taking ARV, of which AZT, 
ddI, and EFV, were suspected culprits in 2, 1, and 1 cases, 
respectively. Three pregnant women treated with a protease 
inhibitor (PI) based regimen developed dyslipidemia during 
pregnancy. EFV was switched to IDV/r in 2 cases at 8 and 
12 weeks' gestation, and dyslipidemia was detected after 
taking IDV/r for 25 and 13 weeks, respectively. For the 
other, the ART was changed regimen from AZT+3TC+NVP 
to boosted saquinavir and indinavir (SQV+ IDV/r) at 25 
weeks' gestation due to treatment failure; her dyslipidemia 
was detected after 13 weeks of the new regimen. 
Pregnancy Outcomes 
  The modes of delivery among the 246 pregnant women 
were normal labor (72.0%), caesarean section (19.0%), vac-
uum extraction (2.8%), and forceps extraction (0.8%). 
Among the 49 women who delivered by caesarean section, 
indications included previous caesarean section (30.6%), 
cephalo-pelvic disproportion (18.4%), and breech presenta-
tion (10.2%). Four had elective caesareans section due to 
low CD4 count; 208 (84.6%) had full-term deliveries, 25 
(10.2%) pre-term, and one stillbirth; 209 (85.0%) had no 
delivery-related complication, 17 (6.9%) had pre-term labor 
pain, 4 (1.6%) premature membrane rupture, and 4 (1.6%) 
pre-eclampsia. Pre-term delivery was significantly higher 
among pregnant women on combined ART and among those 
who started PMTCT in labor because of no ANC (19.4% and 
Table 1.  Maternal Characteristics of Pregnant HIV-Infected  Women, Antenatal Care and HIV History (n=246) 
 
No. of Pregnant Women (%) 
Characteristics   Combined ART 
(N = 40) 
PMTCT During ANC 
(N = 164) 
PMTCT in Labor 
(N = 42) 
P value 
Age: median (min- max) 
Occupation:  
     Laborer  
     Housewife (not working) 
Marital status: Married 
Number of spouse(s) ever:  
            median (min- max) 
Firstly detected HIV in the current  
pregnancy 
Years of known HIV status:  
             median (min-max) 
CDC classification 
             A 
             B 
             C 
Median CD4 count 
(min-max) 
Median gestational age at first visit   
(weeks)(min-max) 
30 (19 - 41) 
 
31 (77.5%) 
9 (22.5%) 
29 (72.5%) 
 
1 (1 - 3) 
 
52.5% 
 
2 (1 - 13) 
 
37 (92.5%) 
2 (5.0%) 
1 (2.5%) 
240 
(2 - 566) 
19.5 
(6 - 36) 
26 (17 - 39) 
 
143 (87.2%) 
21 (12.8%) 
103 (62.8%) 
 
1 (1 - 4) 
 
89.6% 
 
1 (1 - 9) 
 
163 (99.4%) 
0 
1 (0.6%) 
361 
(25 - 996) 
19.5 
(5 - 40) 
27 (16 - 38) 
 
31 (73.8%) 
11 (26.2%) 
16 (38.1%) 
 
1 (1 - 2) 
 
86.7% 
 
1 (1 - 5) 
 
40 (95.2%) 
1 (2.4%) 
1 (2.4%) 
298 
(211 - 376) 
38 
(8 - 41) 
0.015 
 
0.064 
 
0.003 
 
0.17 
 
0.00 
 
0.00 
 
0.06 
 
 
0.00 
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19%, respectively), than among those receiving PMTCT 
during ANC (6.9%, p=0.02). The incidence of pre-term labor 
pain among the pregnant women who initiated PMTCT dur-
ing ANC was significantly lower than the other two groups 
(p = 0.01). However, when factors affecting maternal status--
elderly pregnancy, multigravida, low CD4 count, and ane-
mia--were examined by multivariate analysis, only pregnant 
women who started PMTCT in labor had a significant asso-
ciation with pre-term delivery (p value = 0.01). 
  Four infants (1.6%) had congenital defects (stillbirth with 
hydrocephalus, sensorineural hearing loss, gastroscrisis, and 
polydactyly). Only 2 (0.8%) had congenital pneumonia. 51 
infants showed the results of perinatal HIV infection; the 
perinatal HIV infection rate was 3.9%. None of the infants 
born to pregnant women who received combined ART had 
perinatal HIV infections. Overall, the incidence of low 
birthweight was high, at 49 (20.0%), comprising 39 low and 
10 very low. Infants born to pregnant women who started 
PMTCT in labor had a higher incidence of both low birth-
weight (8; 19.0%), and very low birthweight (5; 11.9%) than 
those receiving PMTCT during ANC (p=0.065). The inci-
dence of low Apgar score was 3.6%; of whom 55.6% were 
 
Fig. (1). All adverse events among 246 pregnant HIV-infected women receiving antiretroviral drugs for either combined antiretroviral ther-
apy and prevention of mother to child HIV transmission.  
Table 2.  Adverse ARV Events in Pregnant Women Receiving Antiretroviral Drugs During Antenatal Care (n=204) 
 
Antiretroviral Drugs 
Adverse Events  (%) 
(n=204)  Combined ART (%)  
(n=40) 
PMTCT During ANC (%)  
(n=164) 
P Value 
Anemia  13 (6.4)  6 (15.0)  7 (4.3)  0.02 
Vomiting  4 (2.0)  3 (7.5)  1 (0.6)  0.02 
Dyslipidemia  3 (1.5)  3 (7.5)  0 (0)     0.01 
Hepatotoxicity and rash  1 (0.5)  1 (2.5)  0 (0)  0.20 
Total  21 (10.4)  13 (32.5)  8 (4.9)  < 0.001 
 
Table 3.  CD4 Count Level Associated with Adverse ARV Events Among Pregnant Women (n=161) 
 
CD4 Count (cells/l) 
Adverse Events  (%) 
(n=161)  Less than 200 (%) (n=29)  Above or Equal 200 (%) (n=132) 
P Value 
Anemia  12 (7.5)  5 (17.2)   7 (5.3)  0.04 
Vomiting  4 (2.5)  1 (3.4)  3 (2.3)  0.55 
Dyslipidemia  3 (1.9)  1 (3.4)  2 (1.5)  0.45 
Hepatotoxicity and rash  1 (0.6)  1 (3.4)  0 (0)  0.18 
Total  20(12.4)  8 (27.6)  12 (9.1)  0.01 
91.5
5.3
1.6
1.2 0.4
No adverse event
Anemia
Vomiting
Dyslipidemia
Heptotoxicity
and rash
 12    The Open AIDS Journal, 2009, Volume 3  Areechokchai et al. 
low and the rest very low, including one stillbirth (Agar 
score = 0). Low Apgar scores were significantly higher 
among infants born to pregnant women who started PMTCT 
in labor (11.9%; p=0.004). 
DISCUSSION 
  Despite the positive impact of antiretroviral drugs on 
HIV-related morbidity and mortality, increased duration of 
ART has been associated with complications. In the PMTCT 
scenario, many studies have reported achievement in HIV 
transmission risk reduction [9]. However, a number of preg-
nant women experienced the typical adverse effects of ARV 
such as anemia, nausea and vomiting, aminotransferase ele-
vation, or hyperglycemia. Reported data have conflicted on 
whether combined ART during pregnancy is associated with 
adverse pregnancy outcomes, such as pre-term delivery [10]. 
Additionally, limited data on the potential teratogenicity of 
antiretroviral drugs in human have been reported [11]. In this 
study, 40 (16.3%) of 246 pregnant women received com-
bined ART, of which none showed perinatal HIV infection. 
PMTCT reduced the perinatal HIV-infection rate of 3.9% in 
this study, consistent with the findings of previous studies 
[12, 13]. Unfortunately, combined ART was significantly 
associated with adverse events, especially anemia in preg-
nancy. The incidence of adverse events in this study was 
lower than the 15% reported in a previous study in Thailand 
[14]. This finding might be explained by the clinical setting, 
at which only clinically oriented adverse events were inves-
tigated further. However, when adjusting the sample size by 
exclusion of women not used AZT, the incidence of adverse 
events among AZT-based regimens was up to 10.4% 
(95%CI: 6.5% - 15.3%). 
  Most of the pregnant women (89.2%) received AZT for 
PMTCT or combined regimens. Therefore, anemia and nau-
sea/vomiting were expected to be common. 3.8% -38% of 
pregnant women in general population will develop anemia 
during pregnancy, depending on nutritional status and tri-
mester [15]. CD4 cell count < 200 cells/μL was significantly 
associated with anemia, but not nausea/vomiting, dyslipide-
mia, or hepatotoxicity. Even though > 50% of the combined 
ART in this study contained NVP, only 1 case of hepatotox-
icity was reported, which could be explained by no CD4 cell 
count cutoff associated with an increased risk of NVP hepa-
totoxicity in women [16] and fewer HBV coinfected cases in 
this study. Anemia can also be affected by maternal HIV 
status. In pregnancy, in the general population, haemoglobin 
levels usually drop early in the first trimester of gestation, 
and reverse after the second to third trimesters [15]. In con-
trast, in this study, the median haemoglobin level of the 
pregnant women in AZT-related anemia was clear early in 
the second trimester after the initiation of AZT, and was sus-
tained at a lower level until delivery. Median hematocrit in 
anemia showed a similar decreasing pattern in all, other than 
a rapid rise in hematocrit at delivery among the pregnant 
women with adverse AZT-related anemia. This increment 
might be explained by the anemia management interventions 
pre-delivery, reduced AZT dosage in 2 cases, substitution 
with d4T in 2 cases, and blood transfusion in 3 cases. In the 
pregnant women receiving AZT for PMTCT, routine com-
plete blood counts should be performed as early as 4 weeks 
after taking AZT. Anemia should be corrected promptly, to 
prevent intrauterine growth retardation of the infant. 
  Regarding delivery outcomes and complications, the in-
cidence of pre-term delivery was 10.7%, which was similar 
to a previous study in Thailand [14]. When the groups were 
compared by antiretroviral regimen used in pregnancy, preg-
nant women on combined ART had a significantly higher 
rate of pre-term delivery than those starting PMTCT during 
pregnancy (19.4% vs 6.9%, p=0.02), consistent with the 
findings of previous studies [2, 12]. Pre-term delivery was 
also higher among the pregnant women initiating PMTCT in 
labor than among those initiating during pregnancy (19.0% 
vs 6.9%, p=0.02). This might reflect the effect of inadequate 
antenatal care. A stillborn infant was born to a mother start-
ing AZT at 31 weeks’ gestation; hydrocephalus, detected 
simultaneously, was likely the consequence of congenital 
infection rather than an adverse AZT-related event. The inci-
dence of pre-eclampsia was 1.7%, quite similar to the rate in 
the general population (2.8%) [3]. The incidence of pre-
eclampsia among pregnant women receiving combined ART 
was 3.2%, which was contrast to a previous study [3]. 
  Regarding the infants, low birthweight was high (20%), 
compared with 7.9% - 9.3% in a previous study in Thailand 
[14], and 5.9% - 9.2% in another study [17]. The pregnant 
women who started PMTCT in labor had a high percentage 
of low-birthweight infants. Inadequate ANC for pregnant 
women might be the cause of the low birthweight noted in 
our study. However, no significant association between low 
birthweight and time to initiate antiretroviral drug, maternal 
CD4 cell count, or gestational age at first ANC visit was 
found. The rate of low Apgar scores was 3.6%, which was 
significantly higher among the pregnant women who started 
ARV during labor, and the women who visited an ANC 
clinic for the first time at > 28 weeks’ gestation (p=0.004 and 
p=0.01, respectively). These differences might also be the 
effect of no or inadequate ANC. Low Apgar scores should 
be detected among neonates born to pregnant HIV-infected 
women without any history of PMTCT during ANC. No 
birth defect was suspected to be related to ART. Five preg-
nant women who received EFV delivered normal babies. An 
infant with sensorineural hearing loss was born to a pregnant 
woman without history of ANC as a consequence of pre-
term status. There was no evidence to suggest that ART in-
creased the risk of congenital abnormality [18, 19]. 
  In conclusion, antiretroviral therapy for PMTCT or 
treatment for a pregnant HIV-infected woman is beneficial 
and outweighs the risk of adverse effects or the costs of the 
drugs. However, it cannot replace good ANC, which should 
be emphasized for all pregnant HIV-infected women, to 
maximise early and regular ANC visits. 
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